Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - medRxiv, 2021 - medrxiv.org
Background Effective vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - 2021 - pesquisa.bvsalud.org
BackgroundEffective vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
[PDF][PDF] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - researchgate.net
Background Effective vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
[PDF][PDF] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - scholar.archive.org
Background Effective vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
PA Goepfert, B Fu, A Chabanon, MI Bonaparte… - 2021 - europepmc.org
Background Effective vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …
(SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein …